Of growing concern in arthroplasty is the emergence of atypical infections, particularly For this non-randomized non-blinded study, 101 adult patients scheduled for hip or knee surgery were recruited. For each, four 3 mm dermal punch biopsies were collected after administration of anaesthesia, but prior to antibiotics. Prebiopsy skin preparation consisted of a standardized preoperative 2% chlorhexidine skin cleansing protocol and an additional 70% isopropyl alcohol mechanical skin scrub immediately prior to biopsy collection. Two skin samples 10 cm apart were collected from a location approximating a standard direct anterior skin incision, and two samples 10 cm apart were collected from a lateral skin incision (suitable for posterior, direct-lateral, or anterolateral approaches). Samples were cultured for two weeks using a protocol optimized for Aims
Methods
To assess the sustainability of our institutional
bone bank, we calculated the final product cost of fresh-frozen femoral
head allografts and compared these costs with the use of commercial
alternatives. Between 2007 and 2010 all quantifiable costs associated
with allograft donor screening, harvesting, storage, and administration
of femoral head allografts retrieved from patients undergoing elective
hip replacement were analysed. From 290 femoral head allografts harvested and stored as full
(complete) head specimens or as two halves, 101 had to be withdrawn.
In total, 104 full and 75 half heads were implanted in 152 recipients.
The calculated final product costs were €1367 per full head. Compared
with the use of commercially available processed allografts, a saving
of at least €43 119 was realised over four-years (€10 780 per year)
resulting in a cost-effective intervention at our institution. Assuming
a price of between €1672 and €2149 per commercially purchased allograft,
breakeven analysis revealed that implanting between 34 and 63 allografts
per year equated to the total cost of bone banking. Cite this article:
